

ROSEAID Email: Info@roseaid.com Website: https://roseaid.com

FOR IMMEDIATE RELEASE

ROSEAId Announces Strategic Partnership with StrongHer Consulting to Drive Global Investment and Humanitarian Impact in Early Cancer Detection

Houston, **TX**, **– April 1st**, **2025**-<u>ROSEAId</u>, a revolutionary leader in early cancer detection technology, proudly announces its partnership with StrongHer Consulting, LLC, a globally focused strategic marketing and consulting firm with a mission rooted in ecosustainability and humanitarianism. This collaboration aims to secure funding from family offices, venture capitalists, angel investors, and private equity to scale ROSEAId's innovative solutions and expand access to underserved communities worldwide

ROSEAld is transforming the landscape of early cancer detection by addressing the critical shortage of pathology services, particularly in regions with limited medical infrastructure. As the number of qualified practitioners in the pathology industry declines and the burden of sample validation increases, the need for cutting-edge technology becomes more urgent than ever. ROSEAld's advanced analytical tools provide faster, more accurate results, enabling earlier detection that can significantly affect patient outcomes.

"We are thrilled to partner with StrongHer Consulting in our mission to revolutionize early cancer detection," said Joe Rossi, CEO of ROSEAId. "Their global reach and commitment to forward-thinking, eco-sustainable solutions align perfectly with our vision. By leveraging their expansive network across real estate, healthcare, and investment sectors, we will bring transformative technology to communities that need it most. Access to timely and accurate pathology services shouldn't be a privilege — it's a necessity, and together with StrongHer Consulting, we are making this a reality."

This partnership also aligns with the United Nations Association of the USA (UNA-USA) and its commitment to the UN Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-Being), SDG 9 (Industry, Innovation, and Infrastructure), and SDG 10 (Reduced Inequalities). By expanding the reach of ROSEAld's technology, this collaboration supports global efforts to ensure equitable access to life-saving medical advancements.



Wendy Cowan, CEO of StrongHer Consulting and a Board Member and Champion Chair of UNA-USA Broward, will be nominating ROSEAId as a candidate to receive the prestigious SDG award in recognition of its groundbreaking contributions to early cancer detection and global health equity.

As part of this initiative, Cowan will lead a delegation to the Annual Investment Meeting (AIM) in Abu Dhabi, bringing together eco-sustainable champions and investors eager to drive humanitarian impact. Wendy has served as an Ambassador to The Annual Investment Meeting and International Property Show since 2021, opening access to funding for startups and new developments. Through strategic outreach to establish collaborations with health systems, hospitals, and Ministries of Health, through these globally recognized platforms, this delegation aims to foster partnerships that will accelerate the adoption of ROSEAId's technology and broaden its life-saving impact.

"Every project we undertake is tied together by the thread of eco-sustainability and creating a better planet where people and the environment can thrive," added Cowan. "As an advanced scuba diver, I'm deeply committed to protecting our ecosystems — and ensuring equitable healthcare access is a vital part of that mission. ROSEAId's work represents a bold step forward in harnessing technology for humanitarian good, and we are committed to making this vision a global reality."

ROSEAId and StrongHer Consulting invite investors and partners who share their passion for innovation and humanitarian impact to join them in scaling this transformative technology. They encourage hospital systems, teaching hospitals, and healthcare networks to explore collaboration opportunities that will drive better patient outcomes worldwide.

About ROSEAId:

ROSEAId is a leading provider of AI-powered solutions for pathologists, scientists, and healthcare professionals for cancer detection and treatment efficacy. Our platforms enable real-time, accurate quantitative evaluation of tissues using advanced artificial intelligence (AI) algorithms and knowledge engineering supporting remote analysis, collaboration, and streamlined processes for better outcomes. Our Multi-Modal Large Language Foundational Model (MLLFM) transforms the way data is analyzed and simulated for faster and more profound investigation into the intricacies of biological complexities and associations.

For more information or to connect with the delegation heading to the Annual Investment Meeting in Abu Dhabi, please contact:

Media Contact:

Wendy Cowan
Director of Global Opportunities ROSEAId
407-276-6254
wcowan@roseaid.com
Connect with Wendy on LinkedIn: www.linkedin.com/in/globallywendy
https://roseaid.com

